Company profile
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
NASDAQ:BBOTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BBO-8520 | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06917079 | phase1 | recruiting | 2025-03-31 | 2027-08-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
| NCT06625775 | phase1 | recruiting | 2024-10-29 | 2028-11-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors |
| NCT06343402 | phase1 | recruiting | 2024-05-22 | 2031-04-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer |
FDA applications (0)
No records yet.